Pfizer presents growth hormone data ahead of FDA filing

A phase 3 trial has found Pfizer and Opko Health’s once-weekly growth hormone deficiency (GHD) treatment imposes less of a burden than the established daily drug Genotropin. The readout comes one year after a separate study found the once-weekly drug is no more effective than Genotropin, handing an advantage to Ascendis Pharma’s rival long-acting treatment TransCon hGH.